Drugs / Deslorelin
Deslorelin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00080756 | Mar 2004 → Sep 2024 overdue | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, breast cancer | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00001202 | Jan 1985 → Jan 2004 | precocious puberty | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 2 | NCT00001190 | Nov 1983 → Oct 2001 | — | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Deslorelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001202 ↗ |
| Known as | D-TRP LHRH-PEA | ChEMBL registry synonym — accepted as the source's own label CHEMBL2365665 ↗ |
| Known as | DESLORELIN ACETATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2365665 ↗ |
| Known as | Deslorelina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2365665 ↗ |
| Known as | Desloreline | ChEMBL registry synonym — accepted as the source's own label CHEMBL2365665 ↗ |
| Known as | Suprelorin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2365665 ↗ |
| Action | Inhibit | “Deslorelin, an LHRH analog which works by turning off true (central) puberty” NCT00001202 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2365665 ↗ |
| Route | Intranasal | “Patients receive deslorelin, estradiol, and testosterone intranasally once daily (QD) for 6 months.” NCT00080756 ↗ |